Myriad Genetics is touting the results of a meta-analysis that show the company's GeneSight Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD).
The findings from four clinical trials, published April 17 in Pharmacogenomics, showed that GeneSight helped guide the appropriate clinical care of 1,556 patients with MDD and at least one prior antidepressant medication failure. With GeneSight, the patients experienced significantly better remission, response, and symptom improvement. Overall remission improved 49% (p = 0.001), response improved by 40% (p < 0.01), and symptoms improved by 43% (p = 0.019), all of which were statistically significant.
Results were based on the 17-item Hamilton Depression Rating Scale (HAM-D17) among patients whose medication selection was directed by GeneSight test results, compared to unguided or conventional care.